Ranibizumab Injection Uses, Dosage, Side Effects and Interactions
Lucentis
Lucentis is the original ranibizumab, made by Genentech. Its biosimilars are Byooviz, Cimerli, Nufymco and Ranluspec, and 1 more. It comes as an injection.
Susvimo
Susvimo is an original ranibizumab product of its own: the FDA lists it as an original, not a biosimilar. It comes as an injection.
Byooviz
Byooviz (ranibizumab-nuna) is Samsung Bioepis’s biosimilar to Lucentis, approved by the FDA in September 2021. The FDA rates it interchangeable with Lucentis.
Cimerli
Cimerli (ranibizumab-eqrn) is Sandoz’s biosimilar to Lucentis, approved by the FDA in August 2022. The FDA rates it interchangeable with Lucentis.
Nufymco
Nufymco (ranibizumab-leyk) is Zydus Lifesciences Global FZE’s biosimilar to Lucentis, approved by the FDA in December 2025. The FDA rates it interchangeable with Lucentis.
Lucentis is the original ranibizumab. The FDA has approved 5 biosimilars of it, such as Byooviz and Cimerli, and they share this page. What is a biosimilar? ↓
Ranibizumab injection is an eye medicine (a VEGF inhibitor) used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, and, with Lucentis, macular edema after retinal vein occlusion and myopic choroidal neovascularization.
Quick links
Ask Anything About Ranibizumab InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Ranibizumab Injection in Short
- Drug class Vascular Endothelial Growth Factor Inhibitor How the FDA classifies it
What it treatsRanibizumab is used for several retinal (back-of-the-eye) conditions. Lucentis is used for wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
- How you get it Prescription only
- Comes asInjection (in the eye)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
The Pharmacist’s Take
Ranibizumab (Lucentis, or the Susvimo implant) is a standard eye medicine, on the market since about 2006, that blocks VEGF-A, a protein that makes abnormal vessels grow and leak, to treat wet age-related macular degeneration, diabetic macular edema (retinal swelling) and diabetic retinopathy, plus, with Lucentis, swelling after a retinal vein occlusion and abnormal vessel growth from severe nearsightedness. Most people tolerate it well, usually noticing just a red spot on the white of the eye, mild soreness or floaters after a shot. Watch for infection inside the eye (endophthalmitis), the subject of Susvimo's boxed warning, and report eye pain, worsening redness, light sensitivity or vision changes right away.
Key Takeaways From the HelloPharmacist Team
- Expect eye injections at your specialist's office, often monthly, or with Susvimo, an implant refilled every 24 or 36 weeks.
- Call your eye doctor promptly for sudden vision loss, new floaters or flashes of light, which can signal a retinal detachment.
- Ask which version your plan covers, since Byooviz, Cimerli and Nufymco are FDA-licensed interchangeable biosimilars of Lucentis.
- Before Susvimo surgery, tell your eye surgeon about aspirin, NSAIDs or blood thinners, which can raise the risk of bleeding inside the eye.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Ranibizumab Injection.
The Susvimo implant carries a higher risk of endophthalmitis, a serious infection inside the eye. In studies, the rate was up to 3 times higher than with monthly ranibizumab injections into the eye. Many cases involved the thin tissue covering the implant (the conjunctiva) pulling back or wearing away.
Careful handling of this tissue and early repair surgery if it breaks down may lower the risk. Report eye pain, redness, or vision changes right away.
Patient Information Guide for Ranibizumab Injection
What It’s Used For
Ranibizumab treats several retinal conditions, depending on the product:
- Lucentis: wet age-related macular degeneration (AMD)
- Lucentis: macular edema following retinal vein occlusion (RVO)
- Lucentis: diabetic macular edema (DME)
- Lucentis: diabetic retinopathy (DR)
- Lucentis: myopic choroidal neovascularization (mCNV)
- Susvimo (ocular implant): wet AMD, DME, and DR in people who previously responded to at least two intravitreal injections of a VEGF inhibitor
How It Works
Ranibizumab binds to VEGF-A, a protein that drives abnormal blood vessel growth and leakage in the eye. This stops VEGF-A from attaching to its receptors on blood vessel lining cells.
That reduces cell growth, leakage, and new vessel formation, which are involved in these retinal conditions.
Drug Class
Drug Class
- Vascular Endothelial Growth Factor Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Vascular Endothelial Growth Factor Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Vascular Endothelial Growth Factor Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Ranibizumab Injection in the FDA’s index.
From our Patient Information GuideRanibizumab binds to VEGF-A, a protein that drives abnormal blood vessel growth and leakage in the eye. This stops VEGF-A from attaching to its receptors on blood vessel lining cells. Read How Ranibizumab Injection Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Ranibizumab Injection in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Antineovascularisation agents
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Lucentis and Its Biosimilars
The FDA has approved 5 biosimilars to Lucentis, the original ranibizumab, made by Genentech. It rates 4 of them interchangeable.
The original
Lucentis
ranibizumab
Made by Genentech · FDA‑approved 2006
Its 5 biosimilars
- Byooviz ranibizumab-nuna Made by Samsung Bioepis · FDA‑approved September 2021 Interchangeable with Lucentis
- Cimerli ranibizumab-eqrn Made by Sandoz · FDA‑approved August 2022 Interchangeable with Lucentis
- Nufymco ranibizumab-leyk Made by Zydus Lifesciences Global FZE · FDA‑approved December 2025 Interchangeable with Lucentis
- Ranluspec ranibizumab-hkdz Made by Lupin · FDA‑approved June 2026 Interchangeable with Lucentis
- Lucamzi ranibizumab-blrz Made by Xbrane Biopharma AB · FDA‑approved October 2026 Biosimilar, not rated interchangeable
Also ranibizumab, and not biosimilars: Susvimo (Genentech, 2021). The FDA lists it as an original product of its own.
What Is a Biosimilar?
- A biologic is made in living cells, not mixed from chemicals, so no copy of one is exactly identical. That is why a copy is called a biosimilar, not a generic.
- The FDA approves a biosimilar only when it is highly similar to the original and has no clinically meaningful differences in safety or in how well it works.
- It may be approved for fewer uses than the original, and may not come in every strength or device. Its own label lists what it is approved for.
What Does Interchangeable Mean?
- An interchangeable biosimilar can be given in place of the original at the pharmacy without your prescriber writing a new prescription, where state law allows, the way a generic can.
- A biosimilar without that rating works the same way, but needs a prescription written for it.
Why Four Letters After the Name?
- The FDA gives each biologic it licenses now four letters of its own, such as the letters nuna in ranibizumab-nuna. They mean nothing on their own.
- They tell one company’s product from another’s in your records and in safety reports.
Which one will I get? That depends on your prescription, your insurance plan and your pharmacy. Your pharmacist can tell you which one you have and whether a switch is possible.
From the FDA’s Purple Book, its list of licensed biologics, checked November 2026. The definitions follow the FDA’s biosimilar pages.
Dosage
Ranibizumab is always given by an eye specialist, never taken at home. Food does not apply.
- Lucentis is given as an injection into the eye.
- Susvimo is a surgically placed implant that releases the medicine continuously. It is refilled in a procedure every 24 weeks (about 6 months) for wet AMD and DME, or every 36 weeks (about 9 months) for DR.
- With Susvimo, a supplemental ranibizumab injection may be given in the eye if clinically needed.
Follow your eye specialist's schedule. Talk to them if you miss a visit.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Lucentis
Swelling in the retina after a blocked eye vein
For adults
Usual dose 0.5 mg once a month (about every 28 days)
- 0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once a month (approximately 28 days)
Diabetic eye swelling and diabetic eye disease
For adults
Usual dose 0.3 mg once a month (about every 28 days)
- 0.3 mg (0.05 mL of 6 mg/mL solution) by intravitreal injection once a month (approximately 28 days)
Abnormal eye vessel growth from severe nearsightedness
For adults
Starting dose 0.5 mg once a month
- 0.5 mg (0.05 mL of 10 mg/mL solution) initially by intravitreal injection once a month (approximately 28 days) for up to 3 months
- May be retreated if needed
Susvimo
Diabetic retinopathy
For adults
Usual dose 2 mg via the implant, refilled every 36 weeks
- 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo implant with refills every 36 weeks (approximately 9 months)
Extra treatment while wearing the Susvimo implant
For adults · Supplemental
Usual dose 0.5 mg injection if needed
- 0.5 mg (0.05 mL of 10 mg/mL) intravitreal ranibizumab injection in the affected eye if clinically necessary
Side Effects
Most side effects involve the eye. The most common are:
Common side effects
- Bleeding on the white of the eye (conjunctival hemorrhage)
- Eye pain
- Vitreous floaters (spots or specks in vision)
- Increased pressure in the eye
- Vitreous detachment
- Cataract
- Blurred vision or visual disturbance
- Foreign body sensation or eye irritation
- Eye irritation or a feeling that something is in the eye
- Dry eye
When to get medical help
- Get help right away for eye pain, increasing redness, light sensitivity, or sudden vision changes, which could signal infection (endophthalmitis) or retinal detachment.
- Report any sudden vision loss, new floaters, or flashes of light promptly.
- With Susvimo, report any signs that could be linked to the implant, such as conjunctival erosion or retraction, implant movement, or vitreous hemorrhage (bleeding inside the eye), without delay. Some of these can occur without symptoms.
- Seek care if vision keeps getting worse after Susvimo implantation. A small drop in vision often occurs in the first two months.
- Tell your doctor about any serious inflammation in the eye.
Less often, people had colds, cough, nausea, or headache. Seek care quickly for severe eye pain, worsening redness, or vision loss, since these can signal infection or retinal detachment.
Warnings and Precautions
- Endophthalmitis (serious eye infection): the Susvimo implant has a higher rate than monthly eye injections, and early treatment helps protect vision.
- Retinal detachment: can cause vision loss and needs prompt treatment.
- Implant problems with Susvimo: dislocation, septum dislodgement, bleeding in the eye, and tissue breakdown or blebs over the implant may need surgery.
- Vision dip after Susvimo surgery: vision often decreases over the first two months.
- Inflammation: postoperative inflammation can happen, mostly in the first week, and usually resolves within a month.
- Other: Lucentis has been linked to increased eye pressure, and careful care is needed with eye tests that could move the implant.
Interactions
Few interactions are described, but these matter:
- Photodynamic therapy (PDT): serious eye inflammation occurred in some people with wet AMD who used Lucentis with PDT, mostly when given about 7 days apart.
- Blood thinners, aspirin, and NSAIDs: may raise the risk of bleeding inside the eye with the Susvimo implant, so your doctor may pause them briefly before surgery.
- Formal interaction studies have not been done with Lucentis.
Interactions Listed in the FDA-Approved Label
From the Ranibizumab Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Photodynamic therapy (PDT)What happensLucentis has been used with PDT; 12 of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation, in 10 of 12 when Lucentis was given 7 days (± 2 days) after PDT.
Read the label’s full interactions text
7 DRUG INTERACTIONS Drug interaction studies have not been conducted with LUCENTIS. LUCENTIS intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (± 2 days) after PDT.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Susvimo must not be used with an infection in or around the eye, active inflammation inside the eye, or a known allergy to ranibizumab or its ingredients.
- Tell your doctor if you are pregnant or may become pregnant. Effective contraception is advised with Susvimo during treatment and for at least 12 months after the last dose.
- Tell your doctor if you are breastfeeding.
- Safety and effectiveness in children have not been established for Susvimo.
- Older adults had similar results and safety in Susvimo studies.
- No dose change is needed for kidney problems.
Overdose
Higher concentrations, up to 2 mg in a smaller volume, have been given to patients with no additional unexpected side effects reported.
Half-Life and How Your Body Processes It
After injection into the eye, only a small amount reaches the bloodstream, and levels there are far lower than in the eye. For Lucentis, the average half-life in the vitreous (the gel inside the eye) is about 9 days. Susvimo releases the medicine continuously from the implant, and it did not build up in the blood with refills. Ranibizumab is an antibody fragment that the body breaks down, and kidney problems do not require dose changes.
Storage
Store SUSVIMO initial fill needle kit at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ranibizumab Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Ranibizumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is ranibizumab used for?
How is ranibizumab given?
What side effects should I expect?
Why does Susvimo have a boxed warning?
Should I tell my doctor about my blood thinners or aspirin?
Is ranibizumab safe during pregnancy?
Is ranibizumab injection available over the counter?
When was ranibizumab injection first available?
What is the brand name of ranibizumab injection?
What is the generic name of Lucentis?
What drug class is ranibizumab injection?
What strengths does ranibizumab injection come in?
Where can I read the ranibizumab injection prescribing information (package insert)?
Is there a biosimilar for Lucentis?
Is ranibizumab injection gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Ranibizumab Injection
Skip the scrolling. Ask in your own words and get an answer from Ranibizumab Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Ranibizumab Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Ranibizumab Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Ranibizumab Injection Forms and Strengths (How It Comes)
Ranibizumab Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Ranibizumab Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Lucentis is used for wet AMD, macular edema after RVO, DME, DR, and mCNV.
- Susvimo is used for wet AMD, DME, and DR in people who previously responded to at least two intravitreal VEGF inhibitor injections.
- Susvimo is delivered continuously through a surgically placed eye implant, with refills by a trained physician.
- Susvimo refills are every 24 weeks for wet AMD and DME, and every 36 weeks for DR.
- Susvimo must not be given as a bolus intravitreal injection or substituted with other ranibizumab products.
- Supplemental 0.5 mg ranibizumab injections may be given with the Susvimo implant in place if clinically necessary.
Ranibizumab Injection on the U.S. Market: Products, Makers and Brands
How Ranibizumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 3 Ranibizumab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2006. Brand names in the directory today include Lucentis and Susvimo; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished injection, solution (5) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Ranibizumab Injection Is Used (Medicaid Data)
How many Ranibizumab Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Ranibizumab Injection prescribed? Of the 1,682 medications we measure, Ranibizumab Injection ranks #857 by Medicaid prescriptions — more than 49% of them.
Utilization by Ranibizumab Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
0.05 ML ranibizumab 10 MG/ML Prefilled Syringe Most dispensed
1 of 2 listed NDCs had Medicaid claims. RxNorm 1864423
0.05 ML ranibizumab 6 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2045501
0.05 ML ranibizumab-eqrn 6 MG/ML Injection
2 of 2 listed NDCs had Medicaid claims. RxNorm 2612675
0.05 ML ranibizumab-eqrn 10 MG/ML Injection
2 of 2 listed NDCs had Medicaid claims. RxNorm 2612684
0.05 ML ranibizumab-nuna 10 MG/ML Injection
1 of 5 listed NDCs had Medicaid claims. RxNorm 2602353
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 7 of the 13 listed Ranibizumab Injection NDCs had Medicaid claims.
Compare Ranibizumab Injection Products
A representative set of FDA-listed product records for Ranibizumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 6 mg/mL | Intravitreal | Genentech, Inc. | BLA | View NDC → |
| 10 mg/mL | Intravitreal | Genentech, Inc. | BLA | View NDC → |
| 100 mg/mL | Intravitreal | Genentech, Inc. | BLA | View NDC → |
Showing 3 of 3 products — FDA National Drug Code Directory. See every product, package size and price: browse all 3 Ranibizumab Injection NDCs →
Ranibizumab Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Ranibizumab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Ranibizumab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Ranibizumab Injection FDA Approval History
How Ranibizumab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Ranibizumab Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Ranibizumab recall since July 2021. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo O… Lots: Lot/Exp: a) 3499188, Exp 10/31/2022; Lot 3523071, Exp 6/30/2023; b) 3456735, Exp 10/23/2026; 3456737; Exp 10/29/2026; 3477671, Exp 10/31/2026; 3480781, Exp 12/19/2026; 3506526, Exp 02/25/2027; 3506531, Exp 04/15/2027 FDA record D-0025-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Ranibizumab Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 10
- Forms in current FDA listings
- 2 of 2
RxCUI 595060 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1724210Its 8 strengths (SCD)-
0.05 mL ranibizumab 10 mg/mL
RxCUI 643193 -
0.05 mL ranibizumab 6 mg/mL
RxCUI 1306074 -
0.05 mL ranibizumab-eqrn 10 mg/mL
RxCUI 2612684 -
0.05 mL ranibizumab-eqrn 6 mg/mL
RxCUI 2612675 -
0.05 mL ranibizumab-leyk 10 mg/mL
RxCUI 2744887 -
0.05 mL ranibizumab-leyk 6 mg/mL
RxCUI 2744897 -
0.05 mL ranibizumab-nuna 10 mg/mL
RxCUI 2602353 -
0.1 mL ranibizumab 100 mg/mL
RxCUI 2584857
-
0.05 mL ranibizumab 10 mg/mL
-
Dose form (SCDF) Prefilled SyringeIn current FDA listings
RxCUI 1864422Its 2 strengths (SCD)-
0.05 mL ranibizumab 10 mg/mL
RxCUI 1864423 -
0.05 mL ranibizumab 6 mg/mL
RxCUI 2045501
-
0.05 mL ranibizumab 10 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Ranibizumab Injection Supply and Shortage Status
Whether Ranibizumab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Ranibizumab Injection Brand Names
Ranibizumab Injection has 5 brand names on record: Lucentis, Susvimo, Byooviz, Cimerli and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Ranibizumab Injection: Manufacturers and Labelers
One company lists Ranibizumab Injection products with the FDA. By number of product records, the largest are Genentech, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Ranibizumab Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genentech, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →